

# Competitive fitness of *Staphylococcus aureus* against nasal commensals depends on biotin biosynthesis and acquisition

 Kevser Bilici<sup>1,2,3</sup>, David Gerlach<sup>3</sup>, Laura Camus<sup>1,2</sup>, Simon Heilbronner<sup>1,2,3,4,\*</sup>
<sup>1</sup>Interfaculty Institute of Microbiology and Infection Medicine Institute for Medical Microbiology and Hygiene, UKT, 72076 Tübingen, Germany

<sup>2</sup>Cluster of Excellence EXC 2124 Controlling Microbes to Fight Infections, 72076 Tübingen, Germany

<sup>3</sup>Faculty of Biology, Microbiology, Ludwig-Maximilians-Universität München, 82152 Martinsried, Germany

<sup>4</sup>German Center for Infection Research "DZIF" Partnersite Tübingen, 72076 Tübingen, Germany


\*Corresponding author. Faculty of Biology, Biozentrum der LMU, Großhaderner Straße 2-4, 82152 Martinsried, Germany. E-mail: Simon.Heilbronner@bio.lmu.de

## Abstract

The human nasal microbiome can serve as a reservoir for pathogens. In particular, the opportunistic pathogen *Staphylococcus aureus* can be a member of the nasal microbiome increasing the risk of subsequent infections. The nasal carriage of *S. aureus* is known to be positively and negatively impacted by nonpathogenic species, suggesting interactions between the pathogen and commensals, but the underlying molecular mechanism remains largely unclear. Herein we demonstrate that *S. aureus* competes with nasal commensals for the coenzyme biotin. Biotin is crucial for all living organisms and we show that depletion of biotin impairs *S. aureus* growth and membrane integrity. We found the nasal cavity to be a biotin-limited environment, suggesting competition for the coenzyme within the microbiome. For some nasal commensals and *S. aureus*, we observed biotin prototrophy and all strains released biotin into the environment. In contrast, other commensals and especially coagulase-negative staphylococci (CoNS) were found to be biotin auxotrophs and strongly reliant on prototrophic strains under biotin-limited conditions. We show that high-affinity biotin uptake systems are used by prototrophic and auxotrophic strains alike and represent crucial factors to optimize competitive fitness of species in co-culture. Together, our data show that biotin-mediated interactions occur between the species of the human nasal microbiome and provide evidence for interspecies competition and co-dependency.

## Graphical abstract

### Biotin-dependent interactions between bacteria in the nasal microbiome


**Keywords:** *S. aureus*; biotin; nasal colonisation; nasal microbiome; competitive fitness

Received: 16 May 2025. Revised: 6 October 2025. Accepted: 31 October 2025

© The Author(s) 2025. Published by Oxford University Press on behalf of the International Society for Microbial Ecology.

 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

## Introduction

*Staphylococcus aureus* is an important human pathogen and causes superficial skin and soft tissue infections as well as life threatening invasive diseases such as sepsis, meningitis, pneumonia, and endocarditis [1]. As an opportunistic pathogen, *S. aureus* colonizes the anterior nares of ~30% of the human population [1–3]. A link between *S. aureus* nasal carriage and development of subsequent infection by the same strain is well known [4], but molecular reasons impacting carriage status remain largely unknown. However evidence is gathering that interactions with the nasal microbiome can be of critical importance [5–13]. For example, *Corynebacterium* spp, *S. epidermidis*, and *S. lugdunensis* can antagonize *S. aureus* colonization [6, 9, 13, 14]. Some antagonizing interactions are caused by direct or indirect inhibition by antimicrobial compounds [14–17] while others remain poorly understood and seem more complex.

The human nasal cavity is a low-nutrient environment. Metabolomic analysis has shown, that nasal secretions contain low concentrations of mono- and disaccharides as well as of amino acids [18]. Trace metals are limited due to the secretion of chelating molecules [19, 20] while other trace nutrients such as vitamins were not detectable [18]. This suggests two possible interactions at the interface of the nasal microbiome and the nasal environment. Firstly, nutritional limitation might trigger strict competition for limited, essential nutrients or, secondly, bacteria might cooperate and engage in cross-feeding interactions by sharing public goods [21]. It is not known if such interactions occur between *S. aureus* and nasal commensals and involved nutrients as well as the effects of the interactions on *S. aureus* are unclear.

Vitamins are micronutrients that are crucial for the metabolism of all living organisms. In particular, vitamins of the water soluble B-group serve as cofactors in different enzymatic pathways needed for proliferation of microorganisms [22, 23]. Biotin (vitamin B7) is an essential cofactor for enzymes catalyzing carboxylation, decarboxylation, and transcarboxylation reactions needed in different metabolic pathways, including gluconeogenesis, fatty acid synthesis, and amino acid catabolism [24]. Plants, some prokaryotes and fungi are able to synthesize biotin *de novo* while humans are auxotrophic. In bacteria four conserved enzymes BioF, BioA, BioD, and BioB are needed to produce biotin from pimeloyl-CoA. Depending on the organism, the pimeloyl moiety is provided by different pathways, needing different additional proteins BioW and BioI [25–27] or BioC and BioH [28–30] or BioZ [31]. *S. aureus* is biotin prototrophic and possesses the biotin operon *bioDABFWX* (Fig. 1). In brief, pimelic acid is converted to pimeloyl-CoA by BioW (pimeloyl-CoA synthase). At this point, BioX may also act as an acyl carrier protein involved in the synthesis of pimeloyl-CoA [25]. BioF (KAPA synthase) then mediates the reaction to 7-keto-8-aminopelargonic acid (KAPA) with a subsequent reaction to 7,8-diaminopelargonic acid (DAPA) directed by BioA (DAPA aminotransferase). Following the synthesis of dethiobiotin (DTB) by BioD (dethiobiotin synthase) biotin is formed using the biotin synthase BioB. Biotin biosynthesis is a metabolically costly pathway because at least six enzymes and 19–20 molecules of ATP equivalents are needed to produce one molecule of biotin [32, 33]. The last reaction of biotin biosynthesis namely, the cleavage of two S-adenosyl-methionine (SAM) by BioB to form the tetrahydrothiophene ring is the main energy consuming reaction, needing six ATP equivalents [33].

In addition to *de novo* synthesis, bacteria are able to acquire biotin from the environment using the biotin transporters BioY

or YigM/BioP. BioY is the substrate-binding component (S component) of an energy-coupling factor (ECF)-type ABC transporter. The *bioY* gene, usually occurs in an operon with the genes encoding the transmembrane protein (T component), and the homo- or hetero-oligomeric ATPases (A component) [34, 35]. ECF-type transporter are known to be high-affinity micronutrient uptake systems in prokaryotes with affinities in the low nanomolar to picomolar range [35]. Thereby ECF-type transporters allow the smallest traces of costly metabolites to be scavenged [35]. YigM/BioP belongs to the carboxylate/amino acid/amine family of secondary active transporters, which are mainly found in *Gammaproteobacteria* and *Epsilonproteobacteria* [36–39]. *Escherichia coli* and *S. aureus* are known to be prototrophic but also to import biotin from the environment via YigM/BioP and BioY, respectively [40].

The importance of biotin biosynthesis and uptake for *S. aureus* in the context of nutritional limitation and microbial competition within the nasal cavity remains unclear. Herein we show biotin availability to be crucial for *S. aureus* growth and membrane integrity. *S. aureus* as well as several nasal commensals produce and release biotin to the environment. In contrast, other commensals and especially coagulase-negative staphylococci (CoNS) were found to be biotin auxotrophic and profited strongly from the presence of biotin prototrophic strains in a biotin-limited environment. High-affinity biotin uptake systems were used by prototrophic and auxotrophic strains alike and mediated direct competition for biotin between the members of the nasal microbiome.

## Material and methods

### Chemicals

If not stated otherwise, reagents were purchased from Sigma.

### Bacterial strains and growth conditions

Bacterial strains are listed in Suppl. Tab. S1. Depending on the experiment, overnight cultures were performed in either TSB (Oxoid, CM0129T) or BHI containing 0.2% Tween80 (BHI-T) at 37°C with agitation. Tetracycline (12.5 µg/ml) or chloramphenicol (10 µg/ml) was added where needed to maintain plasmids pC183-S3 and pIMAY, respectively (Suppl. Tab. S1/S2).


### Creation of marker less deletion mutants and chromosomal complementation

Deletion mutants in *S. aureus* USA300 JE2 were created as previously described [41]. In brief: For *bioA* and *bioY*, 500 bp flanking regions upstream and downstream of the genes were amplified from chromosomal DNA by using A/B and C/D primers (Suppl. Tab. S2) with overlapping sequences. A 1-kb deletion fragment with an ATG-TAA scar was created using spliced overlap extension PCR (SOE-PCR), cloned into pIMAY by restriction digestion and used to transform *S. aureus* USA300 JE2. Mutants were created using allelic exchange as described [41].

For genomic complementation, a silent mutation creating a restriction site (*Bam*HI for *bioA* and *Sma*I for *bioY*) was introduced into the wildtype allele by SOE-PCR. The constructs were cloned into pIMAY and used for reinsertion of the allele into the mutants by allelic replacement.

For creating fluorescent *S. aureus* strains, the GFP-expressing plasmid pC183-S3 was used to transform *S. aureus* using standard procedure.

All used oligonucleotides and plasmids are summarized in Suppl. Tab. S2.



**Figure 1.** Schematic diagram of biotin biosynthesis and transport in *S. aureus* USA300. Genes and corresponding enzymatic functions are indicated. Briefly, pimelic acid is converted to pimeloyl-CoA by BioW (pimeloyl-CoA synthase, SAUSA300\_2369). BioX (SAUSA\_2368) may act as an acyl carrier protein involved in the synthesis of pimeloyl-CoA. BioF (KAPA synthase, SAUSA300\_2370) mediates the reaction to 7-keto-8-aminopelargonic acid (KAPA) which subsequently undergoes transamination reaction by BioA (DAPA aminotransferase, SAUSA300\_2372) to form 7,8-diaminopelargonic acid (DAPA). Following the synthesis of dethiobiotin (DTB) by BioD (dethiobiotin synthase, SAUSA300\_2373), biotin is formed using the biotin synthase BioB (SAUSA300\_2371). In addition, biotin can be transported by the ECF-type transporter BioY (SAUSA300\_2233). Chemical structures were created by using the InChI from PubChem and the chemical sketch tool of PDB.

### Streptavidin-treated tris minimal succinate medium and agar

Tris minimal succinate medium (TMS) was prepared as previously described [42] with the exception of adding 10 g CAS amino acids (Bacto, Gibco Thermo Fisher, 223050) and 27.67 g Di-sodium succinate hexahydrate (Merck, 8.20151.0500). After autoclaving the TMS medium, 0.01% (v/v) Streptavidin agarose (Merck, 69203) was added to the medium and stirred overnight at 4°C for at least 18 h. The medium was sterile filtrated on the next day by using a Nalgene Rapid-Flow filter from Thermo Scientific (0.2 μm). After sterile filtration following chemicals were added to 1 l Streptavidin-treated TMS medium (sTMS): 1 ml of 1 M MgCl<sub>2</sub> (Sigma Aldrich, M8266-100G), 1 ml of 0.1 M CaCl<sub>2</sub> (Sigma Aldrich, C5670-100G), 1 ml of 22 mg/ml L-cysteine (Sigma-Aldrich, 1.02838.0100), and 2 ml of 10 mg/ml L-tryptophan (Sigma-Aldrich, 93 659-50G). After adding the supplements, the medium was stored at 4°C. A vitamin stock was prepared by adding 25 μl of 5 mg/ml cyanocobalamin (Merck, 5.24950.0010), 5 μl of 20 mg/ml 4-aminobenzic acid (Sigma Aldrich, A9878-25G), 6.25 μl of 40 mg/ml nicotinic acid (Merck, 72 309-100G), 6.25 μl of 20 mg/ml D-pantothenic acid hemicalcium salt (Merck, 21 210-5G-F), 7.5 μl of 50 mg/ml pyridoxamine dihydrochloride (Merck, 545 068-5GM), 5 μl of 50 mg/ml thiamine

hydrochloride (Roth, T911.2), 5 μl of 50 mg/ml riboflavin (Sigma, R4500-5G) to 1187.5 μl ddH<sub>2</sub>O. The vitamin stock was stored at -20°C. On the day of experiment vitamins from vitamin stock were added freshly in a 1:1000 dilution to sTMS.

For preparing sTMS agar, TMS medium was prepared as described above with 1.5% European Agar (BD Diagnostic, 257 353). After autoclaving the TMS medium, 0.05 mg/ml Streptavidin (Roth, 6073.2), and all supplements (MgCl<sub>2</sub>, CaCl<sub>2</sub>, L-cysteine, L-tryptophan and vitamins, as mentioned above) were added and plates were poured. So freshly prepared agar was used for all experiments.

### Growth analysis in sTMS

**Generation of the inoculum:** Bacteria were grown to stationary phases overnight in either TSB (*S. aureus* USA300 JE2 and mutants) or BHI-T (all nasal isolates, *E. coli* BW25113 and *E. coli* BW25113 *yigM::Kan*) at 37°C with agitation. Cultures were centrifuged for 1 min at 15871 rcf and washed once with PBS. Cells were adjusted to OD<sub>600</sub> = 0.1 and 1 μl was used to inoculate 1 ml of sTMS (final OD<sub>600</sub> = 0.0001). **Supplementation with biotin:** When appropriate, final biotin concentrations (0.015625 nM to 4 nM) were added using 1 μl or 1000-fold concentrated stock solutions to 1 ml of

sTMS. For generation of spent medium, nasal bacteria were grown to stationary phase overnight in BHI-T at 37°C with agitation, harvested by centrifugation (15 871 rcf) and washed once with PBS. 10 ml sTMS medium were inoculated to an OD<sub>600</sub> of 0.05 and grown for 24 h (stationary phase) at 37°C with agitation. Cells were removed by centrifugation (10 min at 3197 rcf), the supernatants were collected and sterile filtered using a 0.45 µM Millex-HA filter (SLHA033SB). Sterility was confirmed by plating of 200 µl on TSA plates and supernatants were stored until use at 4°C. Spent medium was diluted to 25% by mixing 250 µl with 750 µl fresh sTMS. Growth curve generation: After inoculation 500 µl of the sTMS was transferred to a 48-well microplate (Nunc, Thermo Scientific) and growth was monitored automatically by measuring the OD<sub>600</sub> every 15 min for 25 h to 40 h in an Epoch2 reader (BioTek, Agilent) at appropriate temperatures (30°C, 37°C or 45°C) with double orbital shaking.

### Quantification of biotin levels

For biotin level determination the IDK Biotin ELISA-Kit from Immundiagnostik (K8141) was used according to the manufacturer instructions.

### Human and animal body fluids

Blood was drawn from healthy human volunteers as well as from cotton rats in accordance with ethical allowance from the legal authority in Tübingen (Project numbers 369/2018BO2 and IMIT 0/21 G). Human serum was gained by centrifugation (8000 rcf for 10 min) of blood drawn using heparinized tubes from three female and one male volunteer (23–45 years). Cotton rat plasma was obtained from fresh blood samples that were centrifuged (8000 rcf for 10 min).

Nasal secretions were collected from healthy human volunteers (25–45 years; two females and three males) in accordance with ethical allowance by the legal authority in Munich (Project Nr.: 24-0654). Flow of nasal secretions was induced by mild physical activity for 5 min in a –20°C room and collected by aspiration. The secretions were stored at –80°C and centrifuged (8000 rcf for 10 min) prior to use.

All human samples were taken with informed written consent.

### Crude cell extracts and streptavidin blot

For standard experiments under biotin-saturation, cultures were grown in either TSB (*S. aureus* USA300 JE2 and mutants) or BHI-T (all nasal isolates, *E. coli* BW25113 and *E. coli* BW25113 *yigM::Kan*) and used directly. For experiments reflecting biotin-limited conditions, prototrophic strains were cultivated overnight in TSB/BHI-T, harvested by centrifugation (1 min at 15871 rcf) and washed once with PBS. Bacteria were adjusted to OD<sub>600</sub> = 0.05 in 10 ml sTMS (in 100 ml flasks) and the cultures were grown for 24 h at 37°C with agitation. Overnight cultures (1 ml of OD<sub>600</sub> = 1) from different media (TSB/BHI-T/sTMS) was harvested by centrifugation (1 min at 15871 rcf) and washed three times in PBS. The bacterial pellets were resuspended in 100 µl PBS and transferred to tubes containing glass beads (MN Bead Tubes Typ B, 740812.50). Cells were disrupted using FastPrep-24 (6.5 m/s for 60 sec) and centrifuged (1 min at 15871 rcf). Supernatants were transferred into fresh Eppendorf tubes and centrifuged again (1 min at 15871 rcf) to remove all remaining glass beads. 50 µl of the supernatant was mixed with 12.5 µl Lämmli buffer (BioRad, 1610747) and boiled for 10 min at 100°C in a heating block. 15 µl were loaded on two 13% SDS-PAGE (ROTIPHORESE Gel 30 (37.5:1)) gels. One gel was stained with BlueSafe (NZYtech, MB15201) as loading control and the other one was used for the streptavidin blot.

For the streptavidin blot, the proteins were blotted on a nitrocellulose membrane after separation using the semi-dry blotter Trans-Blot (BioRad). The membrane was incubated at room temperature in the dark in blocking buffer (Thermo Scientific, 37542) for 30 min on a shaking platform. The blocking buffer was discarded and the membrane was incubated with the streptavidin-AP conjugate (Merck/Roche, 11089161001) diluted 1:1000 in 10 ml blocking buffer and incubated as before. The membrane was washed twice in TBS-T (Tris-buffered saline with Tween20, Roth, 1061.1) for 5 min and once with TBS (Tris-buffered saline, Roth, 1060.1) at RT and in the dark. To detect alkaline phosphatase activity a staining solution with 1 ml 0.1% NBT (Biomol, 06428.1) and 9 ml Na<sub>2</sub>CO<sub>3</sub> buffer (9.2 mM Na<sub>2</sub>CO<sub>3</sub>, 40 mM Na<sub>2</sub>CO<sub>3</sub>, pH 9.5) and a spatula tip of BCIP (Roth, 6368.2) was prepared. The membrane was incubated shaking on a platform at RT in the staining solution until bands became visible (30–45 min). The blot was documented by using a commercial scanner (Cannon; 800 dpi) without densitometry-based correction.

### RNA extraction and quantitative RT-PCR

**Sample preparation:** *S. aureus* USA300 JE2 from overnight cultures in BHI-T were harvested (1 min at 15871 rcf) and washed once with PBS. Bacteria were adjusted to OD<sub>600</sub> = 0.05 in 10 ml sTMS (in 100 ml flasks), different concentrations of biotin (0, 1, 4, and 10 nM) were added and the cultures were grown to mid-log phase (~5 h) at 37°C with agitation. The pellet was resuspended in 1 ml Trizol (Invitrogen) and transferred to tubes containing glass beads (MN Bead Tubes Typ B, 740812.50). Cells were disrupted using FastPrep-24 (6.5 m/s for 2x 30 sec) and centrifuged (1 min at 15871 rcf). Supernatants were transferred into fresh Eppendorf tubes and stored at –80°C overnight. **RNA isolation and cDNA synthesis:** For RNA isolation, the samples were first thawed at RT. After adding 200 µl chloroform, the samples were vortexed for 30 s and incubated for 3 min at RT. After centrifugation at 12 000 × g for 15 min at 4°C (Eppendorf Centrifuge 5415R), 600 µl of the supernatants (aqueous phase) were transferred into new Eppendorf tubes filled with 500 µl isopropanol. The samples were inverted 30 times and incubated for 10 min at RT prior centrifugation at 12 000 × g for 20 min at 4°C (Eppendorf Centrifuge 5415R). The pellet was washed once with 500 µl 70% EtOH and centrifuged at 12 000 × g for 20 min at 4°C (Eppendorf Centrifuge 5415R). After removing the supernatants, the pellets were dried for 1 h under the hood. Residual DNA was removed by DNase treatment using the DNase I, RNase-free of Thermo Scientific (EN0521) and incubation at 37°C for 30 min. After adding 90 µl nuclease-free water (Qiagen, 129114), RNA samples were cleaned up using the NucleoSpin RNA Clean-up Kit (Macherey-Nagel, 740948.50) and RNA concentrations were measured with the nanodrop (FastGene NanoSpec Photometer, FG-NP01, NIPPON Genetics). RNA samples were snap-frozen in liquid nitrogen and stored at –80°C. For cDNA synthesis, 200 ng RNA and the iScript Adv cDNA Kit for RT-qPCR (Bio-Rad, 1 725 038) was used. The cDNA was snap-frozen in liquid nitrogen and stored at –80°C. **qPCR:** For qPCR, primers for the housekeeping gene *gyrB* and the gene of interest *bioA* were designed using Primer3plus (Suppl. Tab. S2) and mixed to a 25 µM per primer stock in nuclease-free water (Qiagen, 129114). A master mix with 150 nM primer (end concentration), 2x QuantiNova SYBR Green PCR Kit (Qiagen, 208054) and water was prepared and 5 µl was transferred to a 96-well Hard-Shell PCR plates (Bio-Rad, HSP9655). A concentration of 50 ng cDNA in 5 µl total volume was also transferred to the plate and mixed properly. The plate was sealed with Microseal “B” seal (Bio-Rad, MSB1001) and run in a C1000 Touch Thermal Cycler

with the CFX96 Touch Real-Time PCR detection system (Bio-Rad) under following conditions: 50°C for 90 sec, 95°C for 10 min, and 39 cycles at 95°C for 15 s, 60°C for 30 sec, and subsequently 95°C for 15 sec and 60°C for 45 sec.

### Membrane fluidity assay

Bacteria from overnight cultures in TSB were harvested (1 min at 15871 rcf) and washed once with PBS. Bacteria were adjusted to OD<sub>600</sub> = 0.05 in 10 ml sTMS (in 100 ml flasks), different concentrations of biotin were added and the cultures were grown for 24 h at 37°C with agitation. Cells corresponding to 1 ml OD<sub>600</sub> = 1 were harvested and frozen at -20°C until usage.

To determine the membrane fluidity, the Membrane Fluidity Kit from Abcam (ab189819) was used according to the manufacturer's protocol. Pellets stored at -20°C were thawed and washed once with 400 μl PBS + 20% sucrose. After centrifugation at 8000 rcf for 5 min, the supernatants were discarded and the pellets were treated with 400 μl 20% sucrose, 0.01% F-127 and 10 μM PDA for 1 h in the dark at RT. The samples were centrifuged as above, washed once with 400 μl PBS + 20% sucrose and taken up in 200 μl PBS + 20% sucrose. Two technical replicates of 100 μl were transferred into a black 96-well microtiter plate (Greiner, 655 097) and the fluorescence was measured by excitation at 360 nm and emission at 405 nm (monomer) and 460 nm (excimer). Higher membrane fluidity correlates with higher excimer to monomer ratio.

### In silico analysis

Genome sequence of *S. aureus* USA300 FPR3757 and assembled genomes of species from our collection were screened for annotated core biotin biosynthesis genes *bioD*, *bioA/bioK*, *bioB*, *bioF* encoded either in ORFs or distributed in the genomes, as well as biotin transporter genes *bioY* and *yigM/bioP* using Artemis [43]. A BLAST search was performed using reference genes of *S. aureus* USA300 FPR3757 *bioD* (SAUSA300\_2373), *bioA* (SAUSA300\_2372), *bioB* (SAUSA300\_2371), *bioF* (SAUSA300\_2370), *bioY* (SAUSA300\_2233), and *yigM/bioP* of *P. aeruginosa* PA01 (PA3474) using NCBI BLAST. Additionally, whole genomes were blasted against the reference genes to identify positive hits using NCBI BLAST [44]. All BLAST results are summarized in Suppl. Tab. S3.

Genetic relatedness of nasal commensals used in this work was visualized by similarity of the 16S rRNA loci. The respective sequences were obtained from NCBI Refseq in all cases except for *C. kefirresidentii*. Here the 16S rRNA locus was directly retrieved from the respective WGS data of the used isolate. The obtained sequences were aligned using the Culstal Omega algorithm provided in the msa package [45]. A phylogenetic tree was created from the aligned sequences using the UPGMA method provided in the phangorn package [46].

### Liquid co-cultural growth in sTMS

Bacteria were grown overnight in BHI-T and 12.5 μg/ml tetracycline was added for fluorescent *S. aureus* strains containing the GFP-expressing plasmid pC183-S3. Cells were harvested (1 min at 15871 rcf) and washed once with PBS. *S. aureus* USA300 JE2 and mutant strains were adjusted to an OD<sub>600</sub> = 0.1 in PBS and commensals were adjusted either to OD<sub>600</sub> = 0.1 (for 1:1 ratio), 0.001 (for 100:1 ratio; used for *Klebsiella michiganensis* 44, *Proteus mirabilis* 90, *Klebsiella oxytoca* 218, and *Bacillus cereus* 272), 1 (for 1:10 ratio used for *S. aureus* 198) or 10 (for 1:100 ratio used for CoNS except *S. haemolyticus* 147 (for SHae147: 1:1)) in PBS. In triple co-cultures, 1 μl of each commensal suspension together with 1 μl of OD<sub>600</sub> = 0.1 of the fluorescently labeled *S. aureus* strain was mixed in 1 ml sTMS medium and 500 μl was transferred to a 48-well

microplate (Nunc, Thermo Scientific). Growth was monitored by measuring the OD<sub>600</sub> and fluorescence (Em. 480 nm, Ex. 520 nm and Gain 50) every 15 min for 48 h in a BioTek Synergy H1 Reader (Agilent) at 30°C with orbital shaking. By plotting the fluorescence values against the OD<sub>600</sub>, the fluorescence level at OD<sub>600</sub> = 0.5 was determined and relative proportion of labeled *S. aureus* strains and unlabeled competitors calculated. To determine the fitness of the GFP-labeled strains, obtained OD values (start OD and determined relative end OD) from the cogrowth were background corrected and used to calculate the relative fitness for the GFP-labeled strain (GLS) against the nasal competitor strain (NCS) as previously described [47].

$$\text{Relative fitness}_{\text{GLS}} = \frac{(\text{End OD}_{\text{GLS}} \times \text{Start OD}_{\text{NCS}})}{(\text{End OD}_{\text{NCS}} \times \text{Start OD}_{\text{GLS}})}$$

Fitness improvement against competitor strains of USA300 JE2 wildtype over the JE2 Δ*bioY* mutant was quantified as log<sub>10</sub>-residual of the relative fitness of WT to the assumed equal fitness.

$$\text{Fitness improvement}_{\text{WT}} = \log_{10} \left( \frac{\text{Relative fitness}_{\text{WT}}}{\text{Relative fitness}_{\Delta\text{bioY}}} \right)$$

### Co-cultural growth on sTMS agar plates

Biotin-depleted sTMS agar was prepared as described above. Bacteria from BHI-T overnight cultures were collected (1 min at 15871 rcf) and washed once with PBS. For different nasal isolates used as a lawns, OD<sub>600</sub> was adjusted to 0.05 and streaked on plates using sterile cotton swabs. For *S. aureus* JE2 pC183-S3 and *S. aureus* JE2 Δ*bioY* pC183-S3 grown as spot, OD<sub>600</sub> was adjusted to 1, a 10-fold dilution series was prepared in PBS and 10 μl were spotted on the lawns. The plates were incubated for 48 h at 37°C. Growth of fluorescently labeled *S. aureus* strains were documented by taking photos of the plates with the Intas UV system (Intas GDS Touch 2, Exposure time: 1500) and the FastGene Blue/Green LED flash light (Nippon Genetics; FG-11) and quantified by determination of the minimal dilution that enable visible growth.

## Results

### Appropriate biotin levels are required for normal *S. aureus* USA300 JE2 physiology

*S. aureus* USA300 (FPR3757) encodes the *bioDABF* operon (SAUSA300\_2373; SAUSA300\_2372; SAUSA300\_2371; SAUSA300\_2370) suggesting that the strain is able to synthesize biotin endogenously from pimeloyl-CoA. Indeed *S. aureus* USA300 JE2 WT (JE2 WT) was able to proliferate in biotin-deficient Tris Minimal Succinate medium (sTMS) (Fig. 2A). This medium was used throughout our experiments as it allows robust, biotin-dependent growth of *S. aureus* as well as of many nasal commensal species. In contrast, a *bioA* deletion mutant (Δ*bioA*) failed to grow under the same conditions and chromosomal reversion (Δ*bioA*::*bioA*) rescued the phenotype in sTMS (Fig. 2A). Similar phenotypes were observed in biotin-deficient Synthetic Nasal Medium [18] which mimics the nutritional surrounding within the nasal cavity more closely and is characterized by slower growth rates on lower yields (Suppl. Fig. S1A). In contrast, the *bioA*-deficient strain did not show fitness defects when grown in biotin-rich Tryptic Soy Broth (TSB), speaking against a general fitness disadvantage or secondary site mutations (Suppl. Fig. S1B). We performed titration experiments in sTMS and SNM20 medium to identify the critical

biotin concentration needed by *S. aureus*. Biotin enhanced the proliferation of the  $\Delta bioA$  strain in a dose-dependent manner, with 4 nM being sufficient for normal levels of growth akin to the wildtype strain (Fig. 2B and Suppl. Fig. S1A/C). *S. aureus* is known to proliferate within the human host during infection as well as within the human nasal cavity during colonization. We used biotin ELISA assays to investigate if exogenous biotin might be a relevant nutritional source in these habitats. In agreement with previous studies [36], we found human serum to contain ~1 nM biotin (Fig. 2C). Nasal secretions contained very similar concentrations showing that biotin is a scarce nutrient in the nose. However, biotin levels are within the physiologically relevant range for *S. aureus* in both human habitats. As described before, rodent serum contains a much higher concentration of biotin (~100 nM) suggesting that biotin restriction is not relevant in rodent model systems [36].

The effects of biotin limitation on *S. aureus* physiology are not well known. Only two *S. aureus* enzymes are thought to be biotinylated [40, 48]: firstly, the pyruvate carboxylase (Pyc) which enables usage of pyruvate for gluconeogenesis [49] and, secondly, the acetyl-CoA carboxylase (Acc) a crucial enzyme for long-chain fatty acid biosynthesis [50]. *S. aureus* USA300\_FPR3757 encodes Pyc (SAUSA300\_1014) and two alleles of Acc (SAUSA300\_1476 and SAUSA300\_1564). Streptavidin blots of JE2 WT whole cell extracts showed two distinct bands, corresponding to Pyc (128.5 kDa) and Acc (17 kDa). The Acc band appears at ~25 kDa rather than predicted 17 kDa, a phenomenon that has been reported previously [51] (Fig. 2D). However, two bands indicating expression of both Acc proteins (16.8 kDa and 17.12 kDa) could not be identified. A *pyc*-deficient mutant (*pyc::Erm*, derived from the Nebraska Transposon Mutant Library (NTML) [52]) showed absence of the 128.5 kDa band in streptavidin blots (Fig. 2D) but did not show a growth deficit under biotin-limiting conditions (Fig. 2E). This suggests that the enzyme is dispensable under the experimental conditions used. Mutants with defects in any of the two *acc* genes were neither available in the NTML nor in more dense transposon mutant libraries [53], suggesting essentiality. This is in line with previous reports showing that inactivation of *acc* results in fatty acid auxotrophy [54]. Accordingly, we hypothesized that biotin limitation interferes with fatty acid biosynthesis in the  $\Delta bioA$  mutant. Indeed, compared to the wildtype, strict biotin limitation (100 pM) resulted in a strong increase of membrane fluidity in the  $\Delta bioA$  mutant. Increased biotin supplementation rescued the phenotype (Fig. 2F). Appropriate membrane fluidity is needed for adaptation to different temperatures [55–57]. Calculation of generation times of the  $\Delta bioA$  mutant showed that biotin limitation heavily impacted fitness, especially at a growth temperature of 30°C (Fig. 2G).

### Biotin transporter BioY improves the fitness of *S. aureus* and reduces biotin loss to the environment


Between 19 and 20 molecules of ATP are necessary for the production of a single molecule of biotin, making its biosynthesis extremely cost-intensive. We speculated that biotin import might improve the fitness of *S. aureus* by sparing cellular resources. At 30°C, supplementation of biotin deficient medium with 4 nM biotin drastically increased the growth of the prototrophic JE2 WT strain (2.5 h compared to 3.9 h per generation) (Fig. 3A). In contrast, growth-stimulatory effects of exogenous biotin were less pronounced at 45°C and absent at 37°C (Fig. 3A). This reinforces the notion of biotin biosynthesis/acquisition being particularly

important at low temperatures. Furthermore, increasing concentrations of biotin (up to 4 nM) resulted in decreased expression of the biotin biosynthesis gene *bioA* (Fig. 3B). This is in line with previous results [58] and suggest that *S. aureus* reduces expression of the costly biosynthesis pathway when internal concentrations are sufficient. *S. aureus* encodes the biotin specific ECF-type transporter BioY for which the hydrolysis of two molecules ATP is needed to import one molecule of the coenzyme. An isogenic deletion mutant of *bioY* ( $\Delta bioY$ ) was used to test the contribution of the ECF-type transporter. The  $\Delta bioY$  strain did not show abnormal phenotypes when grown with excess biotin (Suppl. Fig. S2A/B) but an increased lag time along with a reduced final optical density was apparent when grown in presence of 4 nM biotin which is restrictive but sufficient to allow WT levels of growth of the biotin auxotrophic  $\Delta bioA$  mutant (Fig. 3C). These phenotypes were abrogated by chromosomal reversion of the mutation ( $\Delta bioY::bioY$ ). In contrast to our initial hypothesis, we observed that the  $\Delta bioY$  mutant displayed an abnormal growth regardless of the presence of biotin (Fig. 3C and D). This phenotype is best explained by the assumption that endogenously synthesized biotin is released and subsequently recaptured by BioY. To further investigate this, we measured the biotin concentration in spent culture supernatants of JE2 WT and  $\Delta bioY$  strains grown without exogenous biotin. Extracellular biotin was not detectable in the supernatants of the WT strain, while those of the  $\Delta bioY$  mutant contained ~500 pM (Fig. 3E). Both strains reached comparable CFU counts at the end of the experiment (Fig. 3E) and did not differ in their autolysis profiles (Suppl. Fig. S2E) suggesting that differences were caused by BioY-dependent regain of biotin and not by different levels of cell death. Using spent culture supernatants of JE2 WT and mutant, we found that only the *bioY* deficient ( $\Delta bioY$ ) strain's supernatant fostered growth of the biotin auxotroph ( $\Delta bioA$ ) (Fig. 3F). All phenotypes of *bioY* deficiency were also observed in SNM20 (Suppl. Fig. S2C, D, F, G). Taken together, these data suggest that BioY plays a dual role for the fitness of *S. aureus*. Firstly, it allows acquisition of biotin derived from external sources and secondly it minimizes the loss of endogenously produced biotin. This improves the fitness of the producer but also prevents its usage by other bacteria.

### Nasal commensals show diverse biotin auxotrophies and overproduction phenotypes.

We speculated that release and BioY-dependent uptake of biotin might foster interactions between *S. aureus* and nasal commensals because of biotin limitation in the nose. To investigate this, we used a strain collection of human nasal bacteria isolated from healthy human volunteers [59].

We chose representative strains and investigated their genome sequences for the presence of genes for biotin biosynthesis and uptake (Fig. 4A). We assigned bacteria as prototroph when possessing all four core genes *bioD*, *bioA*, *bioB*, and *bioF*, and found putative biotin auxotrophy to be a frequent trait. Among the CoNS, *S. hominis*, *S. lugdunensis*, *S. warneri*, *S. capitis*, and *S. haemolyticus* possessed incomplete operons for biotin biosynthesis. The same was true for *Dolosigranulum pigrum*, *Finnegoldia magna*, *Micrococcus luteus*, *Corynebacterium accolens*, and *C. kefirresidentii*. Genes encoding putative biotin acquisition systems were identified in all strains with the exception of *C. propinquum* and *Moraxella osloensis*. However, biotinylated enzymes were detected in representative strains of all species (Suppl. Fig. S3A, B and C) suggesting that auxotrophic strains depend on exogenously available biotin. Biotinylated proteins were also detected in prototrophic strains grown in the absence of exogenous biotin,




**Figure 2.** Effects of biotin limitation on *S. aureus* physiology. (A) Growth under biotin-limited conditions. Strains were inoculated to an OD<sub>600</sub> = 0.0001 in 500  $\mu$ l streptavidin-treated (biotin-free) TMS medium (sTMS) in a 48-well plate and growth was monitored every 15 min for 25 h at 37°C using an Epoch2 orbital reader. For reasons of clarity, only values taken every 2.5 h are displayed. Mean and SD of three independent experiments is shown. (B) Biotin titration. *S. aureus*  $\Delta$ bioA was inoculated as in (A) and supplemented with different biotin concentrations. Growth was monitored as in (A) and OD<sub>600</sub> at timepoint 24 h was plotted against the biotin concentration. Mean and SD of three independent experiments are shown. (C) Biotin levels in cotton rat plasma and different human body fluids. Biotin levels were measured using the IDK biotin ELISA kit (K8141) from Immundiagnostik. Mean and SD of four cotton rat plasma samples, four human serum samples and five human nasal secretions are shown. (D) Biotinylated enzymes in *S. aureus*. Streptavidin blot (bottom) and SDS-Page (top) of crude extracts of *S. aureus* USA300 JE2 WT and the pyruvate carboxylase mutant from the Nebraska Transposon Mutant Library (NTML) (*pyc::Erm*) grown overnight in TSB. Biotinylated enzymes were detected by using the alkaline phosphatase activity of the streptavidin-AP conjugate. (E) Growth of the *Pyc*-deficient strain. Growth was monitored as in (A). Mean and SD of three independent experiments are shown. (F) Membrane fluidity. *S. aureus* USA300 JE2 WT and  $\Delta$ bioA were grown in sTMS in flasks with various concentrations of biotin. Membrane fluidity was assessed using the kit from Abcam (ab189819). Mean and SD of three independent experiments are shown. Statistical analysis was performed using ordinary one-way ANOVA. (G) Biotin-dependent growth at different temperatures. The strain  $\Delta$ bioA was grown in sTMS in the presence of either 4 nM or 100 pM biotin at different temperatures and the generation times in exponential phases were calculated. Mean and SD of three experiments are shown statistical analysis was performed using ordinary two-way ANOVA ( $P < .0001$ ).

verifying the validity of our detection method and supporting the idea that biotin is endogenously synthesized (Suppl. Fig. S3D).

We tested the ability of representative strains to proliferate in biotin-deficient medium. None of the strains predicted to be biotin auxotrophs were able to grow under these conditions (Fig. 4B and Suppl. Fig. S4A). However, several strains predicted to be prototrophic for biotin also failed to grow (including *S. epidermidis*, *S. pettenkoferi*, *M. osloensis*, and all tested *Corynebacteria*). In agreement with previous reports [60], addition of extracellular biotin improved the growth of CoNS as well as of *M. luteus* up to 5-fold. However, exogenous biotin did not rescue the growth of *Corynebacteria* (Fig. 4B and Suppl. Fig. S4B). This suggests that under our experimental conditions biotin limitation was growth-limiting for several isolates, while additional limitations existed for others.

All strains that were capable of proliferation under biotin-free conditions reached final cell densities between  $1 \times 10^8$  and  $5 \times 10^9$  CFU / ml (Suppl. Fig. S4C). Spent medium of all strains contained biotin but the amounts varied considerably (Fig. 4C). All *S. aureus* strains released low amounts of biotin (~200 pM) while two *B. cereus* strains produced 15 to 25-fold more. All nasal Gram-negative species released 6–8-fold more biotin than *S. aureus*. We included the laboratory strain *E. coli* BW25113 and the strain *yigM::Kan*, lacking the biotin importer. Supernatants of BW25113 contained similar amounts of biotin compared to those of other Gram-negative species. A trend towards increased biotin accumulation in the *yigM* mutant (*yigM::Kan*) (Fig. 4C) was observed, suggesting that the principle of biotin loss and regain might be conserved across species.



**Figure 3.** Effects of exogenous biotin. (A) *S. aureus* USA300 JE2 WT profits from exogenous biotin. *S. aureus* was grown in presence (+) or absence (–) of 4 nM biotin at various temperatures in 48 well plates and growth was monitored using an Epoch2 plate reader. Growth rates in exponential phase were calculated. Mean and SD of three independent experiments are shown. Two-way ANNOVA was used for statistical analysis ( $P < .0001$ ). (B) Downregulation of biotin biosynthesis under physiological levels of biotin. *S. aureus* JE2 WT was grown to mid-log phase in 10 ml sTMS with indicated biotin levels and cells were harvested. The RNA was extracted and transcribed to cDNA. The expressions level of  $\Delta bioA$  was determined by qPCR and normalized to the expression levels of the housekeeping gene *gyrB*. (C, D) Effects of BioY-dependent biotin acquisition. Strains were inoculated in 48 well format to an  $OD_{600} = 0.0001$  in 500  $\mu$ l in sTMS medium with (C) or without (D) supplementation with 4 nM biotin. Growth was monitored every 15 min for 40 h at 30°C using an Epoch2 orbital reader. For reasons of clarity, only values taken every 2.5 h are displayed. Mean and SD of three independent experiments are shown. (E) Biotin levels in sTMS and culture supernatants. Biotin levels and CFU/ml in sTMS and of strains grown for 24 h in 10 ml sTMS were assessed using the IDK biotin ELISA kit (K8141) from Immundiagnostik. Mean and SD of three independent experiments are shown for JE2 WT and  $\Delta bioY$ . Filled circles indicate measurable biotin levels in the supernatants. Filled black squares indicate samples in which no quantifiable biotin could be measured. (F) Growth support of  $\Delta bioA$  by  $\Delta bioY$  supernatants.  $\Delta bioA$  was inoculated to an  $OD_{600} = 0.0001$  in 500  $\mu$ l sTMS containing 25% sterile filtered *S. aureus* USA300 JE2 WT and  $\Delta bioY$  supernatants and growth was monitored in 48-well plates for 40 h at 37°C using an Epoch2 orbital reader. For reasons of clarity, only values taken every 2.5 h are displayed. Mean and SD of three independent experiments are shown.

Altogether these datasets indicate that nasal bacteria show considerable differences within their need of exogenous biotin as well as within their capacity to release biotin to the environment.


### Release of biotin and BioY-dependent uptake promotes interaction of nasal bacteria with *S. aureus*

We used dilute culture supernatants to assess if the different biotin levels produced by nasal commensals increased the proliferation of *S. aureus*. Indeed, the biotin auxotrophic *S. aureus* mutant ( $\Delta bioA$ ) profited from culture supernatants of commensals and the degree of growth promotion was directly correlated ( $r = 0.73$ ;  $P = .0250$ ) to the amount of biotin present in the supernatants (Fig. 5A). Similarly, solid-phase co-culture assays showed that commensals stimulated *S. aureus* growth in a biotin-dependent manner and to very different extents (Suppl. Fig. S5). These data strongly suggest that different levels of biotin are excreted during growth of nasal commensals and that this biotin is accessible to *S. aureus*. In the reciprocal experiments, the dilute culture supernatant of *S. aureus* WT was a poor biotin source for nasal auxotrophic CoNS, while that of the  $\Delta bioY$  mutant

substantially increased the growth of several strains including *S. capitis*, *S. lugdunensis*, *S. haemolyticus*, and *S. pettenkoferi* (Fig. 5B), showing that the strains are able to acquire biotin released by *S. aureus*.

Together our experiments support the hypothesis of biotin-sharing within the nasal microbiome. Biotin is released by *S. aureus* as well as by other prototrophic commensals to form a generally accessible pool. All strains, prototrophic as well as auxotrophic can access this pool, to optimize growth and competitive fitness. However, the relevance of biotin acquisition for *S. aureus* in the context of endogenous biosynthesis and competing microbes remains unclear. To investigate this, we performed competitive fitness analysis to elaborate the fitness advantage associated with expression of BioY for the prototrophic *S. aureus* strain when competing with diverse commensals. *S. aureus* JE2 WT and the isogenic  $\Delta bioY$  mutant were fluorescently labeled by introduction of the GFP-encoding plasmid pC183-S3. Labeled strains showed a fluorescent signal in linear proportion to the optical density (Suppl. Fig. S6). Both labeled strains were grown independently under biotin-limited conditions in the presence of unlabeled competitors. In all cultures a constant increase in





**Figure 5.** Biotin-containing supernatants support *Staphylococci* growth in sTMS. (A) Growth support of *S. aureus*  $\Delta$ bioA by supernatants of nasal commensals. The strain  $\Delta$ bioA was inoculated to an  $OD_{600} = 0.0001$  in 500  $\mu$ l sTMS containing 25% sterile filtered *S. aureus* JE2 WT,  $\Delta$ bioY, and commensal supernatants (EC: *E. coli* BW25113; yigM::Kan: *E. coli* BW25113 yigM::Kan; BC112: *B. cereus* 112; BC272: *B. cereus* 272; KM44: *K. michiganensis* 44; PM90: *P. mirabilis* 90 and KO218: *K. oxytoca* 218). Growth was monitored for 24 h at 37°C in 48-well plates using an Epoch2 orbital reader. Area under the curve was determined after 24 h. Shown are the mean and SD of three independent biological replicates. The relationship between biotin concentration in the supernatant and the growth increase of  $\Delta$ bioA was assessed by computing Pearson correlation coefficient ( $r = 0.73$  and  $P = .0250$ ). (B) Growth of CoNS strains in sTMS with 25% supernatants of *S. aureus* JE2 WT and  $\Delta$ bioY. CoNS strains (SW67: *S. warneri* 67; SHo103: *S. hominis* 103; SHae147: *S. haemolyticus* 147; SC200: *S. capitis* 200; SL239: *S. lugdunensis* 239; SP240: *S. pettenkoferi* 240; SE28: *S. epidermidis* 28; SE202: *S. epidermidis* 202, and SE275: *S. epidermidis* 275) were inoculated to an  $OD_{600} = 0.0001$  in 500  $\mu$ l sTMS containing 25% *S. aureus* JE2 WT or 25%  $\Delta$ bioY supernatant for 24 h at 37°C. Fold change was determined at  $OD_{600} = 24$  h. The mean and SD of three independent biological replicates are shown.

fitness against *S. aureus* (*K. michiganensis* 44 and *B. cereus* 272). Similarly, BioY expression was relevant in competition against two species of comparable fitness to *S. aureus* (*E. coli*, *B. cereus* 112) but of little relevance against two combined species with inferior fitness (*S. warneri* 67, *S. lugdunensis* 239). These data suggest that especially under conditions of severe competition, the improved acquisition / reduced loss of biotin improves the fitness of *S. aureus* substantially.

Increased fitness of the WT compared to the BioY deficient strain was also apparent when bacteria were grown on sTMS agar surfaces, which mimic adherent growth within the nasal cavity more closely. When competing with confluent lawns of commensal competitor bacteria, the BioY-deficient strain needed an inoculum density increased by one to three orders of magnitude to form visible colonies (Fig. 6B and C). This demonstrates that competition for biotin is also relevant during surface attached, biofilm-like growth closely resembling the conditions within the nasal cavity.


## Discussion

Biotin is an essential trace nutrient. Bacteria need low nanomolar concentration of biotin for normal growth. Indeed, 10 nM is needed by *P. aeruginosa* [62] and 10 nM was reported to increase growth rates of *S. aureus* [40]. We found *S. aureus* to require ~4 nM biotin under our experimental conditions. Below this threshold *S. aureus* showed reduced growth yields, especially at 30°C which

mimics the conditions within the nasal cavity where the bacterium is a frequent commensal [63]. While *S. aureus* contains two biotinylated enzymes we identified the acetyl-coA carboxylase (Acc) as the major driver of this phenotype. Acc is important for fatty acid biosynthesis and we found biotin limitation to increase membrane fluidity, suggesting disturbance of membrane integrity which is in line with previous reports [64–66]. Additionally, it was shown that biotin limitation reduced fibrinolytic activity along with production of phosphatase and coagulase and resulted in increased susceptibility to antimicrobials, highlighting the impact of appropriate biotin levels for *S. aureus* physiology and virulence [67]. Pyruvate carboxylase (Pyc), the second biotin-dependent enzyme of *S. aureus* catalyzes the carboxylation of pyruvate to gain oxaloacetate. This is needed to replenish the TCA cycle for gluconeogenesis [68]. However, the C4 carbohydrate succinate is the dominant carbon sources in nasal secretions [18] and within sTMS used herein. It is therefore not surprising that the pyruvate carboxylase was dispensable under our experimental growth conditions.

The interplay between endogenous biosynthesis and BioY-dependent acquisition of exogenous biotin remains poorly understood. However, it is well known that endogenous biosynthesis is controlled by BirA and transcriptionally repressed in the presence of biotin [40, 58]. Most likely this allows the bacterium to save ATP and channel it in other biosynthetic processes.

Our experiments showed BioY to confer a distinct fitness benefit for *S. aureus* with and without exogenous supplementation of biotin. Additionally, bioY deficient strains accumulated more biotin in the supernatant than the wildtype strain, strongly suggesting that *S. aureus* constantly loses endogenously synthesized biotin to the environment and that this problem is minimized by BioY-dependent reacquisition. Similar results were shown for genetically engineered *E. coli* producing vitamin B<sub>12</sub> (cobalamin) [69]. In that study, the cobalamin transporter mutant *AbtUf* accumulated much more vitamin B<sub>12</sub> in the supernatant than the wildtype [69]. The precise mechanism of excretion of central metabolites is not well investigated. However, the most accepted theory is that metabolites are part of the exometabolome due to metabolic overflow [70, 71]. This is mainly described for major fermentation products (e.g. lactate, acetate, and ethanol) but newer assumptions also include secretion of primary metabolites (e.g. amino acids and nucleosides) [71–73]. A strain-specific secretion of isoleucine and other organic acids due to overflow metabolism during growth in eukaryotic cell medium RPMI has also been described for *S. aureus* [74]. Nonetheless, metabolomic data indicate that all secreted intracellular metabolites cannot solely rely and be explained by intracellular metabolic overflow [75]. Other molecular mechanisms resulting in externalization of metabolites could include transport via facilitated diffusion through non-specific mechanosensitive channels with pore sizes of  $\leq 2.8$  nm [76], loss of membrane integrity, and cell lysis [77]. Using *E. coli*, it was shown that uptake of biotin is energy-dependent and works against the concentration gradient while its release is energy-independent and follows the concentration gradient, suggesting a diffusion-like mechanism [38]. Most likely secretion of biotin by *S. aureus* and other prototrophic nasal bacteria is caused by similar mechanisms. Accordingly, central metabolites can be regarded as public goods that can impact the physiology of other species and foster collaborative and competitive activities within bacterial communities. In the context of the nasal microbiome, it has been shown that classically intracellular coproporphyrins are found in culture supernatants of cutibacteria and induce aggregation of *S. aureus* [78]. We found extensive variation in biotin



**Figure 6.** Co-cultivation of JE2 WT and  $\Delta bioY$  with commensals under biotin-limited conditions. Unlabeled bacterial competitor strains were grown with either GFP- labeled *S. aureus* JE2 WT (JE2 WT pC183-S3) or GFP-labeled *S. aureus* JE2  $\Delta bioY$  ( $\Delta bioY$  pC183-S3). (A) For both *S. aureus* strains the competitive fitness index (CF-I) against each competitor was calculated and put in proportion. JE2: *S. aureus* USA300 JE2;  $\Delta bioY$ : *S. aureus* USA300 JE2  $\Delta bioY$ ; SA18: *S. aureus* 18; SA37: *S. aureus* 37; SA146: *S. aureus* 146; SA185: *S. aureus* 185; SA198: *S. aureus* 198; EC: *E. coli* BW25113; *yigM*::Kan: *E. coli* BW25113 *yigM*::Kan; BC112: *B. cereus* 112; BC272: *B. cereus* 272; KM44: *K. michiganensis* 44; PM90: *P. mirabilis* 90, and KO218: *K. oxytoca* 218; SW67: *S. warneri* 67; SHo103: *S. hominis* 103; SHae147: *S. haemolyticus* 147; SC200: *S. capitis* 200; SL239: *S. lugdunensis* 239; SP240: *S. pettenkoferi* 240; SE28: *S. epidermidis* 28; SE202: *S. epidermidis* 202, and SE275: *S. epidermidis* 275. The dashed line represents the assumed equal fitness of JE2 WT and JE2  $\Delta bioY$ . Dots represent mean results of three independent biological replicates for each group (detailed results can be obtained from Suppl. Fig. 7). (B, C) Competition of *S. aureus* JE2 WT and  $\Delta bioY$  against commensals on biotin-deficient sTMS agar. Unlabeled prototrophic bacterial competitor strains were grown as a confluent lawn on sTMS agar plates. GFP-labeled *S. aureus* JE2 WT pC183-S3:GFP and *S. aureus* JE2  $\Delta bioY$  pC183-S3:GFP were dotted in 10-fold dilutions on top of the lawns and dilutions forming spots were quantified. (B) Example plates. Agar plate-based competition of WT and  $\Delta bioY$  against lawns of *E. coli* BW25113 in presence or absence of 10  $\mu$ M biotin. (C) Quantification of co-cultivation on sTMS plates. Growth of 10-fold diluted GFP-labeled *S. aureus* stains on the lawns of diverse prototrophic competitors was quantified as follows: 1: Full bright spot or clear individual colonies; 0.75: bright rims with darker inner areas; 0.5: spot is weak but clearly visible; 0.25: spot is barely visible. Indicated is the mean of three biological replicates. EC: *E. coli* BW25113; *yigM*::Kan: *E. coli* BW25113 *yigM*::Kan; KM44: *K. michiganensis* 44; PM90: *P. mirabilis* 90; KO218: *K. oxytoca* 218; BC112: *B. cereus* 112, and BC272: *B. cereus* 272.

levels released by nasal commensals. Exogenous biotin stimulated biotin-dependent growth of *S. aureus* in a concentration-dependent manner in both cell-free and co-culture experiments. This demonstrated that *S. aureus* profits from biotin released by nasal communities. Similar vitamin-dependent interactions were predicted and demonstrated to shape dynamics within human gut microbiomes [79–86] and, also within marine microbial communities [87].

Vitamin auxotrophies have been shown to drive co-dependency and cross-feeding within different bacterial communities [85, 88, 89]. Here we found biotin auxotrophy to be a common trait in CoNS and in *D. pigrum*. This has also been observed by others [90, 91] and our *in silico* screening suggests that also *F. magna* relies on biotin produced by others. However, experimental evidence to support this is currently lacking. Human nasal secretions contain only ~1 nM biotin. The origin of biotin in nasal secretions remains unclear. It seems possible that it derives from metabolic overflow from nasal commensals, but is equally likely that it derives directly from human cells producing nasal secretions such as goblet cells (which release mucins) [92], glandulae nasales (producing seromucous fluid) [93] or ductus nasolacrimalis (tear fluid) [94] or even from disintegrated epithelial cells [95]. However, despite being available, the biotin concentration is at the low end of the physiologically needed concentration and competition for the cofactor by auxotrophs is most likely fierce. Here it has to be considered that besides biotin, biosynthesis-intermediates might be released and acquired. This might be a relevant source of biotin for species with fragmented biosynthesis pathways as observed for several nasal commensal species. BioY-dependent acquisition of biotin appears to play a dual role for *S. aureus*. Firstly, it allows regain of endogenously synthesized biotin that might otherwise be lost to the environment. Secondly, it effectively reduces the amount of exogenous biotin to minimize the support of competing auxotrophs within the same habitat. In line with this we found that biotin containing culture supernatants of the BioY-deficient strain fostered growth of auxotrophic CoNS, while those of the wildtype did not. Similarly, competitive fitness of auxotrophic commensals was increased when co-cultured with  $\Delta$ bioY strain. Similar observations were made for the cobalamin transporter BtuF mutant in *E. coli* providing more cobalamin during co-culture and making  $\Delta$ btuF a better mutualistic partner [69]. Strains SA18 and SA146 profited strongly from competition with the bioY deficient strain that provides increased levels of biotin. These strains were reported before to be auxotrophic for the amino acid tyrosine and to be adapted to specific bacterial communities providing this amino acid [59]. It seems possible that these strains carry multiple metabolic constraints including reduced biotin biosynthesis that makes them dependent on special producer communities

The concept of metabolic overflow and reacquisition of the publicly available goods might be of general relevance, especially within a nutrient-limited environment such as the nasal cavity. Auxotrophic “cheaters” that rely on the metabolic capacity of other bacteria are frequently observed [87, 96–98]. In the nasal microbiome the sharing of siderophores to satisfy iron requirement is similar to the sharing of biotin. Several nasal commensals do not produce siderophores and are reliant on those produced by others fostering their own fitness and decreasing that of the producer [20].

The acquisition of costly metabolic molecules and the associated downregulation or even inactivation of endogenous metabolic pathways represents a common bacterial strategy to optimize growth. We demonstrate that well defined biotin transporters (*bioY*/*yigM* [34, 99]) are encoded by prototrophic

and auxotrophic strains alike, suggesting a general ability to import extracellular biotin. This appears ecologically worthwhile as acquisition allows sparing of ~18 molecules ATP that can be reallocated towards other cellular processes such as biomass production and replication. Accordingly, stringent transcriptional control of biotin biosynthesis by internal levels is demonstrated for many prototrophic phyla present in the nasal microbiome including *Firmicutes* (*Staphylococcus* spp, *Bacillus cereus*), *Actinobacteria* (*Corynebacteria* spp), and *Proteobacteria* (*E. coli*, *P. mirabilis*, and *M. osloensis*, *Klebsiella* spp [40, 100–104]. Additional, computational analysis regarding conservation of biotin biosynthesis regulators and their DNA-binding motifs suggest tight regulation to be a conserved phenomenon within eubacteria [105].

Specialization of bacteria to synthesize or scavenge biotin might not be due to energetic costs but might also reflect the ecological niche and associated optimal growth rates. Slow growing bacteria may conserve energy by minimizing biosynthesis, while faster growers like *S. aureus* may exploit exogenous nutrients for rapid replication when available. We found most coagulase negative staphylococci to be auxotrophic for biotin suggesting that they are adapted to environmental conditions that supply appropriate amounts of biotin for their dedicated niche and replication rate. In contrast, *S. aureus* produces biotin and appears keen not to lose and share the metabolite with the nasal community. This might indicate that for *S. aureus* the external concentrations are frequently insufficient for its lifestyle which is characterized by strong proliferation and rapid consumption of external resources such as carbohydrates [106].

## Conclusion

In conclusion, our study demonstrates that, despite endogenous synthesis, the acquisition of exogenous biotin is crucial for optimal fitness of *S. aureus*. This is of particular importance in the context of auxotrophic competitors that acquire biotin synthesized and released by other organisms.

## Acknowledgements

We thank Prof. Timothy J. Foster for critically reading and editing this manuscript. We thank Prof. Dirk J. Slotboom for helpful discussion.

## Author contributions

K.B. Conceptualization, Investigation, Formal analysis, Methodology, Validation, Data curation, Visualization, Writing—original draft, Writing—review & editing; D.G. Conceptualization, Software, Formal analysis, Methodology, Data curation, Visualization, Supervision, Writing—review & editing; L.C. Resources, Supervision, Writing—review & editing; S.H. Conceptualization, Methodology, Supervision, Writing—original draft, Writing—review & editing, Project administration, Funding acquisition

## Supplementary material

Supplementary material is available at *The ISME Journal* online.

## Conflicts of interest

None declared.

## Fundings

We acknowledge funding by the German Center of Infection Research "DZIF" TTU 08.708\_00 to S.H. Additionally, we acknowledge infrastructural funding by the Deutsche Forschungsgemeinschaft "DFG" (German Research Foundation) in the frame of Germany's Excellence Strategy—EXC 2124-390 838 134/EXC-2124/1-05.002\_0 (S.H.). We acknowledge support from the Open Access Publication Fund of the LMU.

## Data availability

Sequence data that support the findings of this study have been deposited as BioProject to NCBI with the primary accession numbers PRJNA1199961 and PRJNA1247435. Other data are provided within the manuscript or supplementary information files.

## References

- Wertheim HF, Melles DC, Vos MC. *et al.* The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet Infect Dis* 2005;**5**: 751–62. [https://doi.org/10.1016/S1473-3099\(05\)70295-4](https://doi.org/10.1016/S1473-3099(05)70295-4)
- Noble WC, Valkenburg HA, Wolters CHL. Carriage of *Staphylococcus aureus* in random samples of a normal population. *Epidemiol Infect* 1967;**65**:567–73. <https://doi.org/10.1017/S002217240004609X>
- Sakr A, Brégeon F, Mège J-L. *et al.* *Staphylococcus aureus* nasal colonization: an update on mechanisms, epidemiology, risk factors, and subsequent infections. *Front Microbiol* 2018;**9**:2419. <https://doi.org/10.3389/fmicb.2018.02419>
- Wenzel RP, Perl TM. The significance of nasal carriage of *Staphylococcus aureus* and the incidence of postoperative wound infection. *J Hosp Infect* 1995;**31**:13–24. [https://doi.org/10.1016/0195-6701\(95\)90079-9](https://doi.org/10.1016/0195-6701(95)90079-9)
- Escapa IF, Chen T, Huang Y. *et al.* New insights into human nostril microbiome from the expanded human oral microbiome database (eHOMD): a resource for the microbiome of the human aerodigestive tract. *mSystems* 2018;**3**:e00187-18. <https://doi.org/10.1128/mSystems.00187-18>
- Frank DN, Feazel LM, Bessesen MT. *et al.* The human nasal microbiota and *Staphylococcus aureus* carriage. *PLoS One* 2010;**5**:e10598. <https://doi.org/10.1371/journal.pone.0010598>
- Hardy BL, Merrell DS. Friend or foe: interbacterial competition in the nasal cavity. *J Bacteriol* 2021;**203**:e00480-20. <https://doi.org/10.1128/JB.00480-20>
- Krismer B, Weidenmaier C, Zipperer A. *et al.* The commensal lifestyle of *Staphylococcus aureus* and its interactions with the nasal microbiota. *Nat Rev Microbiol* 2017;**15**:675–87. <https://doi.org/10.1038/nrmicro.2017.104>
- Lina G, Boutite F, Tristan A. *et al.* Bacterial competition for human nasal cavity colonization: role of staphylococcal *agr* alleles. *Appl Environ Microbiol* 2003;**69**:18–23. <https://doi.org/10.1128/AEM.69.1.18-23.2003>
- Liu CM, Price LB, Hungate BA. *et al.* *Staphylococcus aureus* and the ecology of the nasal microbiome. *Sci Adv* 2015;**1**:e1400216. <https://doi.org/10.1126/sciadv.1400216>
- Piewngam P, Otto M. *Staphylococcus aureus* colonisation and strategies for decolonisation. *The Lancet Microbe* 2024;**5**:e606–18. [https://doi.org/10.1016/S2666-5247\(24\)00040-5](https://doi.org/10.1016/S2666-5247(24)00040-5)
- Uehara Y, Nakama H, Agematsu K. *et al.* Bacterial interference among nasal inhabitants: eradication of *Staphylococcus aureus* from nasal cavities by artificial implantation of *Corynebacterium* sp. *J Hosp Infect* 2000;**44**:127–33. <https://doi.org/10.1053/jhin.1999.0680>
- Yan M, Pamp SJ, Fukuyama J. *et al.* Nasal microenvironments and interspecific interactions influence nasal microbiota complexity and *S. Aureus* carriage. *Cell Host Microbe* 2013;**14**:631–40. <https://doi.org/10.1016/j.chom.2013.11.005>
- Zipperer A, Konnerth MC, Laux C. *et al.* Human commensals producing a novel antibiotic impair pathogen colonization. *Nature* 2016;**535**:511–6. <https://doi.org/10.1038/nature18634>
- Liu Q, Liu Q, Meng H. *et al.* *Staphylococcus epidermidis* contributes to healthy maturation of the nasal microbiome by stimulating antimicrobial peptide production. *Cell Host Microbe* 2020;**27**:68–78.e5. <https://doi.org/10.1016/j.chom.2019.11.003>
- Torres Salazar BO, Dema T, Schilling NA. *et al.* Commensal production of a broad-spectrum and short-lived antimicrobial peptide polyene eliminates nasal *Staphylococcus aureus*. *Nat Microbiol* 2023;**9**:200–13. <https://doi.org/10.1038/s41564-023-01544-2>
- Tamkin E, Lorenz BP, McCarty A. *et al.* Airway *Corynebacterium* interfere with *Streptococcus pneumoniae* and *Staphylococcus aureus* infection and express secreted factors selectively targeting each pathogen. *Infect Immun* 2025;**93**:e0044524. <https://doi.org/10.1128/iai.00445-24>
- Krismer B, Liebecke M, Janek D. *et al.* Nutrient limitation governs *Staphylococcus aureus* metabolism and niche adaptation in the human nose. *PLoS Pathog* 2014;**10**:e1003862. <https://doi.org/10.1371/journal.ppat.1003862>
- Burian M, Wolz C, Yazdi AS. Transcriptional adaptation of staphylococci during colonization of the authentic human environment: an overview of transcriptomic changes and their relationship to physiological conditions. *Front Cell Infect Microbiol* 2022;**12**:1062329. <https://doi.org/10.3389/fcimb.2022.1062329>
- Zhao Y, Bitzer A, Power JJ. *et al.* Nasal commensals reduce *Staphylococcus aureus* proliferation by restricting siderophore availability. *ISME J* 2024;**18**:wrae123. <https://doi.org/10.1093/ismejo/wrae123>
- Ghoul M, Mitri S. The ecology and evolution of microbial competition. *Trends Microbiol* 2016;**24**:833–45. <https://doi.org/10.1016/j.tim.2016.06.011>
- Peterson WH, Peterson MS. Relation of bacteria to vitamins and other growth factors. *Bacteriol Rev* 1945;**9**:49–109. <https://doi.org/10.1128/br.9.2.49-109.1945>
- Werkman CH. Vitamin effects in the physiology of microorganisms. *J Bacteriol* 1927;**14**:335–47. <https://doi.org/10.1128/jb.14.5.335-347.1927>
- Tong L. Structure and function of biotin-dependent carboxylases. *Cell Mol Life Sci* 2013;**70**:863–91. <https://doi.org/10.1007/s00018-012-1096-0>
- Bower S, Perkins JB, Yocum RR. *et al.* Cloning, sequencing, and characterization of the *Bacillus subtilis* biotin biosynthetic operon. *J Bacteriol* 1996;**178**:4122–30. <https://doi.org/10.1128/jb.178.14.4122-4130.1996>
- Green AJ, Rivers SL, Cheesman M. *et al.* Expression, purification and characterization of cytochrome P450 biol: a novel P450 involved in biotin synthesis in *Bacillus subtilis*. *J Biol Inorg Chem* 2001;**6**:523–33. <https://doi.org/10.1007/s007750100229>
- Stok JE, De Voss JJ. Expression, purification, and characterization of Biol: a carbon-carbon bond cleaving cytochrome P450 involved in biotin biosynthesis in *Bacillus subtilis*. *Arch Biochem Biophys* 2000;**384**:351–60. <https://doi.org/10.1006/abbi.2000.2067>
- Agarwal V, Lin S, Lukk T. *et al.* Structure of the enzyme-acyl carrier protein (ACP) substrate gatekeeper complex required

- for biotin synthesis. *Proc Natl Acad Sci USA* 2012;**109**:17406–11. <https://doi.org/10.1073/pnas.1207028109>
29. Lin S, Hanson RE, Cronan JE. Biotin synthesis begins by hijacking the fatty acid synthetic pathway. *Nat Chem Biol* 2010;**6**:682–8. <https://doi.org/10.1038/nchembio.420>
  30. Lin S, Cronan JE. Closing in on complete pathways of biotin biosynthesis. *Mol BioSyst* 2011;**7**:1811. <https://doi.org/10.1039/c1mb05022b>
  31. Sullivan JT, Brown SD, Yocum RR. et al. The bio operon on the acquired symbiosis island of *Mesorhizobium* sp. strain R7A includes a novel gene involved in pimeloyl-CoA synthesis. The GenBank accession number for the sequence reported in this paper is AF311738. *Microbiology* 2001;**147**:1315–22. <https://doi.org/10.1099/00221287-147-5-1315>
  32. Feng Y, Zhang H, Cronan JE. Profliigate biotin synthesis in  $\alpha$ -proteobacteria – a developing or degenerating regulatory system? *Mol Microbiol* 2013;**88**:77–92. <https://doi.org/10.1111/mmi.12170>
  33. Sirithanakorn C, Cronan JE. Biotin, a universal and essential cofactor: synthesis, ligation and regulation. *FEMS Microbiol Rev* 2021;**45**:1–18, fuab003. <https://doi.org/10.1093/femsre/fuab003>
  34. Hebbeln P, Rodionov DA, Alfandega A. et al. Biotin uptake in prokaryotes by solute transporters with an optional ATP-binding cassette-containing module. *Proc Natl Acad Sci USA* 2007;**104**:2909–14. <https://doi.org/10.1073/pnas.0609905104>
  35. Rodionov DA, Hebbeln P, Eudes A. et al. A novel class of modular transporters for vitamins in prokaryotes. *J Bacteriol* 2009;**191**:42–51. <https://doi.org/10.1128/JB.01208-08>
  36. Carfrae LA, MacNair CR, Brown CM. et al. Mimicking the human environment in mice reveals that inhibiting biotin biosynthesis is effective against antibiotic-resistant pathogens. *Nat Microbiol* 2019;**5**:93–101. <https://doi.org/10.1038/s41564-019-0595-2>
  37. Piffeteau A, Zamboni M, Gaudry M. Biotin transport by a biotin-deficient strain of *Escherichia coli*. *Biochimica et Biophysica acta (BBA). Biomembranes* 1982;**688**:29–36. [https://doi.org/10.1016/0005-2736\(82\)90575-2](https://doi.org/10.1016/0005-2736(82)90575-2)
  38. Piffeteau A, Gaudry M. Biotin uptake: influx, efflux and countertransport in *Escherichia coli* K12. *Biochimica et Biophysica acta (BBA). Biomembranes* 1985;**816**:77–82. [https://doi.org/10.1016/0005-2736\(85\)90395-5](https://doi.org/10.1016/0005-2736(85)90395-5)
  39. Prakash O, Eisenberg MA. Active transport of biotin in *Escherichia coli* K-12. *J Bacteriol* 1974;**120**:785–91. <https://doi.org/10.1128/jb.120.2.785-791.1974>
  40. Satiaputra J, Eijkelkamp BA, McDevitt CA. et al. Biotin-mediated growth and gene expression in *Staphylococcus aureus* is highly responsive to environmental biotin. *Appl Microbiol Biotechnol* 2018;**102**:3793–803. <https://doi.org/10.1007/s00253-018-8866-z>
  41. Monk IR, Shah IM, Xu M. et al. Transforming the untransformable: application of direct transformation to manipulate genetically *Staphylococcus aureus* and *Staphylococcus epidermidis*. *MBio* 2012;**3**:e00277–11. <https://doi.org/10.1128/mBio.00277-11>
  42. Sebulsky MT, Speziali CD, Shilton BH. et al. PhuD1, a ferric hydroxamate-binding lipoprotein in *Staphylococcus aureus*. *J Biol Chem* 2004;**279**:53152–9. <https://doi.org/10.1074/jbc.M409793200>
  43. Carver T, Harris SR, Berriman M. et al. Artemis: an integrated platform for visualization and analysis of high-throughput sequence-based experimental data. *Bioinformatics* 2012;**28**:464–9. <https://doi.org/10.1093/bioinformatics/btr703>
  44. Altschul SF, Gish W, Miller W. et al. Basic local alignment search tool. *J Mol Biol* 1990;**215**:403–10. [https://doi.org/10.1016/S0022-2836\(05\)80360-2](https://doi.org/10.1016/S0022-2836(05)80360-2)
  45. Bodenhofer U, Bonatesta E, Horejš-Kainrath C. et al. Msa: an R package for multiple sequence alignment. *Bioinformatics* 2015;**31**:3997–9. <https://doi.org/10.1093/bioinformatics/btv494>
  46. Schliep KP. Phangorn: phylogenetic analysis in R. *Bioinformatics* 2011;**27**:592–3. <https://doi.org/10.1093/bioinformatics/btq706>
  47. Schmitz DA, Wechsler T, Mignot I. et al. Predicting bacterial interaction outcomes from monoculture growth and supernatant assays. *ISME. Communications* 2024;**4**:ycae045. <https://doi.org/10.1093/ismeco/ycae045>
  48. Hempel K, Pané-Farré J, Otto A. et al. Quantitative cell surface proteome profiling for SigB-dependent protein expression in the human pathogen *Staphylococcus aureus* via biotinylation approach. *J Proteome Res* 2010;**9**:1579–90. <https://doi.org/10.1021/pr901143a>
  49. Utter MF, Keech DB. Pyruvate carboxylase. *J Biol Chem* 1963;**238**:2603–8. [https://doi.org/10.1016/S0021-9258\(18\)67873-1](https://doi.org/10.1016/S0021-9258(18)67873-1)
  50. Wakil SJ. A malonic acid derivative as an intermediate in fatty acid synthesis. *J Am Chem Soc* 1958;**80**:6465–5. <https://doi.org/10.1021/ja01556a086>
  51. Li SJ, Cronan JE. The gene encoding the biotin carboxylase subunit of *Escherichia coli* acetyl-CoA carboxylase. *J Biol Chem* 1992;**267**:855–63.
  52. Fey PD, Endres JL, Yajjala VK. et al. A genetic resource for rapid and comprehensive phenotype screening of nonessential *Staphylococcus aureus* genes. *MBio* 2013;**4**:e00537–12. <https://doi.org/10.1128/mBio.00537-12>
  53. Yousief SW, Abdelmalek N, Paglietti B. Optimizing phage-based mutant recovery and minimizing heat effect in the construction of transposon libraries in *Staphylococcus aureus*. *Sci Rep* 2024;**14**:22831. <https://doi.org/10.1038/s41598-024-73731-y>
  54. Parsons JB, Frank MW, Rosch JW. et al. *Staphylococcus aureus* fatty acid auxotrophs do not proliferate in mice. *Antimicrob Agents Chemother* 2013;**57**:5729–32. <https://doi.org/10.1128/AAC.01038-13>
  55. Cronan JE, Gelmann EP. Physical properties of membrane lipids: biological relevance and regulation. *Bacteriol Rev* 1975;**39**:232–56. <https://doi.org/10.1128/br.39.3.232-256.1975>
  56. Marr AG, Ingraham JL. Effect of temperature on the composition of fatty acids in *Escherichia coli*. *J Bacteriol* 1962;**84**:1260–7. <https://doi.org/10.1128/jb.84.6.1260-1267.1962>
  57. Quinn PJ. The fluidity of cell membranes and its regulation. *Prog Biophys Mol Biol* 1981;**38**:1–104. [https://doi.org/10.1016/0079-6107\(81\)90011-0](https://doi.org/10.1016/0079-6107(81)90011-0)
  58. Henke SK, Cronan JE. The *Staphylococcus aureus* group II biotin protein ligase BirA is an effective regulator of biotin operon transcription and requires the DNA binding domain for full enzymatic activity. *Mol Microbiol* 2016;**102**:417–29. <https://doi.org/10.1111/mmi.13470>
  59. Camus L, Franz J, Gerlach D. et al. Tyrosine availability shapes *Staphylococcus aureus* nasal colonization and interactions with commensal communities. 2025. <https://www.biorxiv.org/content/10.1101/2025.05.06.651429v1>
  60. Evans JB. Studies of staphylococci with special reference to the coagulase-positive types. *J Bacteriol* 1948;**55**:793–800. <https://doi.org/10.1128/jb.55.6.793-800.1948>
  61. Stubbendieck RM, Straight PD. Multifaceted interfaces of bacterial competition. *J Bacteriol* 2016;**198**:2145–55. <https://doi.org/10.1128/JB.00275-16>
  62. Shi Y, Cao Q, Sun J. et al. The opportunistic pathogen *Pseudomonas aeruginosa* exploits bacterial biotin synthesis pathway to benefit its infectivity. *PLoS Pathog* 2023;**19**:e1011110. <https://doi.org/10.1371/journal.ppat.1011110>

63. Lindemann J, Leiacker R, Rettinger G. et al. Nasal mucosal temperature during respiration. *Clin Otolaryngol* 2002;**27**:135–9. <https://doi.org/10.1046/j.1365-2273.2002.00544.x>
64. Gavin JJ, Umbreit WW. Effect of biotin on fatty acid distribution in *Escherichia coli*. *J Bacteriol* 1965;**89**:437–43. <https://doi.org/10.1128/jb.89.2.437-443.1965>
65. Hugo WB, Davidson JR. Effect of cell lipid depletion in *Staphylococcus aureus* upon its resistance to antimicrobial agents. 1. Lipid depletion induced by biotin deficiency. *Microbios* 1973;**8**: 43–51.
66. Parsons JB, Frank MW, Rosch JW. et al. *Staphylococcus aureus* fatty acid auxotrophs do not proliferate in mice. *Antimicrob Agents Chemother* 2013;**57**:5729–32. <https://doi.org/10.1128/AAC.01038-13>
67. Adekeye JD, Coles EH. Effect of biotin deficiency on some properties of *Staphylococcus aureus* isolates from humans and other animals. *Infect Immun* 1976;**13**:475–9. <https://doi.org/10.1128/iai.13.2.475-479.1976>
68. Gupta R, Gupta N. *Glycolysis and Gluconeogenesis. Fundamentals of Bacterial Physiology and Metabolism*. Singapore: Springer Singapore, 2021, 267–87.
69. Bunbury F, Deery E, Sayer AP. et al. Exploring the onset of B<sub>12</sub>-based mutualisms using a recently evolved *Chlamydomonas* auxotroph and B<sub>12</sub>-producing bacteria. *Environ Microbiol* 2022;**24**:3134–47. <https://doi.org/10.1111/1462-2920.16035>
70. Mo ML, Palsson BØ, Herrgård MJ. Connecting extracellular metabolic measurements to intracellular flux states in yeast. *BMC Syst Biol* 2009;**3**:37. <https://doi.org/10.1186/1752-0509-3-37>
71. Paczia N, Nilgen A, Lehmann T. et al. Extensive exometabolome analysis reveals extended overflow metabolism in various microorganisms. *Microb Cell Factories* 2012;**11**:122. <https://doi.org/10.1186/1475-2859-11-122>
72. Krämer R. Secretion of amino acids by bacteria: physiology and mechanism. *FEMS Microbiol Rev* 1994;**13**:75–93. <https://doi.org/10.1111/j.1574-6976.1994.tb00036.x>
73. Reaves ML, Young BD, Hosios AM. et al. Pyrimidine homeostasis is accomplished by directed overflow metabolism. *Nature* 2013;**500**:237–41. <https://doi.org/10.1038/nature12445>
74. Dörries K, Lalk M. Metabolic footprint analysis uncovers strain specific overflow metabolism and D-isoleucine production of *Staphylococcus aureus* COL and HG001. *PLoS One* 2013;**8**:e81500. <https://doi.org/10.1371/journal.pone.0081500>
75. Pinu FR, Granucci N, Daniell J. et al. Metabolite secretion in microorganisms: the theory of metabolic overflow put to the test. *Metabolomics* 2018;**14**:43. <https://doi.org/10.1007/s11306-018-1339-7>
76. Wang Y, Liu Y, DeBerg HA. et al. Single molecule FRET reveals pore size and opening mechanism of a mechano-sensitive ion channel. *elife* 2014;**3**:e01834. <https://doi.org/10.7554/eLife.01834>
77. Rozen DE, Philippe N, Arjan De Visser J. et al. Death and cannibalism in a seasonal environment facilitate bacterial coexistence. *Ecol Lett* 2009;**12**:34–44. <https://doi.org/10.1111/j.1461-0248.2008.01257.x>
78. Wollenberg MS, Claesen J, Escapa IF. et al. *Propionibacterium*-produced coproporphyrin III induces *Staphylococcus aureus* aggregation and biofilm formation. *MBio* 2014;**5**:e01286–14. <https://doi.org/10.1128/mBio.01286-14>
79. Culp EJ, Goodman AL. Cross-feeding in the gut microbiome: ecology and mechanisms. *Cell Host Microbe* 2023;**31**:485–99. <https://doi.org/10.1016/j.chom.2023.03.016>
80. Magnúsdóttir S, Ravcheev D, De Crécy-Lagard V. et al. Systematic genome assessment of B-vitamin biosynthesis suggests cooperation among gut microbes. *Front Genet* 2015;**6**:148. <https://doi.org/10.3389/fgene.2015.00148>
81. Molina Ortiz JP, Read MN, McClure DD. et al. High throughput genome scale modeling predicts microbial vitamin requirements contribute to gut microbiome community structure. *Gut Microbes* 2022;**14**:2118831. <https://doi.org/10.1080/19490976.2022.2118831>
82. Putnam EE, Goodman AL. B vitamin acquisition by gut commensal bacteria. *PLoS Pathog* 2020;**16**:e1008208. <https://doi.org/10.1371/journal.ppat.1008208>
83. Rodionov DA, Arzamasov AA, Khoroshkin MS. et al. Micronutrient requirements and sharing capabilities of the human gut microbiome. *Front Microbiol* 2019;**10**:1316. <https://doi.org/10.3389/fmicb.2019.01316>
84. Rowley CA, Kendall MM. To B12 or not to B12: five questions on the role of cobalamin in host-microbial interactions. *PLoS Pathog* 2019;**15**:e1007479. <https://doi.org/10.1371/journal.ppat.1007479>
85. Sharma V, Rodionov DA, Leyn SA. et al. B-vitamin sharing promotes stability of gut microbial communities. *Front Microbiol* 2019;**10**:1485. <https://doi.org/10.3389/fmicb.2019.01485>
86. Degnan PH, Taga ME, Goodman AL. Vitamin B 12 as a modulator of gut microbial ecology. *Cell Metab* 2014;**20**:769–78. <https://doi.org/10.1016/j.cmet.2014.10.002>
87. Sultana S, Bruns S, Wilkes H. et al. Vitamin B12 is not shared by all marine prototrophic bacteria with their environment. *ISME J* 2023;**17**:836–45. <https://doi.org/10.1038/s41396-023-01391-3>
88. Embree M, Liu JK, Al-Bassam MM. et al. Networks of energetic and metabolic interactions define dynamics in microbial communities. *Proc Natl Acad Sci USA* 2015;**112**:15450–5. <https://doi.org/10.1073/pnas.1506034112>
89. Noto Guillen M, Rosener B, Sayin S. et al. Assembling stable syntrophic *Escherichia coli* communities by comprehensively identifying beneficiaries of secreted goods. *Cell Systems* 2021;**12**:1064–1078.e7. <https://doi.org/10.1016/j.cels.2021.08.002>
90. Gretler AC, Mucciolo P, Evans JB. et al. Vitamin nutrition of the staphylococci with special reference to their biotin requirements. *J Bacteriol* 1955;**70**:44–9. <https://doi.org/10.1128/jb.70.1.44-49.1955>
91. Brugger SD, Eslami SM, Pettigrew MM. et al. *Dolosigranulum pigrum* cooperation and competition in human nasal microbiota. *mSphere* 2020;**5**:e00852–20. <https://doi.org/10.1128/mSphere.00852-20>
92. Dhanisha SS, Guruvayoorappan C, Drishya S. et al. Mucins: structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. *Crit Rev Oncol Hematol* 2018;**122**: 98–122. <https://doi.org/10.1016/j.critrevonc.2017.12.006>
93. Bojsen-Møller F. XXXII Glandulae nasales Anteriorae in the human nose. *Ann Otol Rhinol Laryngol* 1965;**74**:363–75. <https://doi.org/10.1177/000348946507400207>
94. Paulsen F. *The Human Nasolacrimal Ducts*. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003.
95. Beule AG. Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses. *GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery* 2010;**9**. <https://doi.org/10.3205/CTO000071>
96. Giri S, Oña L, Waschina S. et al. Metabolic dissimilarity determines the establishment of cross-feeding interactions in bacteria. *Curr Biol* 2021;**31**:5547–5557.e6. <https://doi.org/10.1016/j.cub.2021.10.019>

97. Mee MT, Collins JJ, Church GM. et al. Syntrophic exchange in synthetic microbial communities. *Proc Natl Acad Sci USA* 2014;**111**:E2149–56. <https://doi.org/10.1073/pnas.1405641111>
98. Zhang X, Reed JL. Adaptive evolution of synthetic cooperating communities improves growth performance. *PLoS One* 2014;**9**:e108297. <https://doi.org/10.1371/journal.pone.0108297>
99. Côté J-P, French S, Gehrke SS. et al. The genome-wide interaction network of nutrient stress genes in *Escherichia coli*. *MBio* 2016;**7**:e01714–6. <https://doi.org/10.1128/mBio.01714-16>
100. Feng Y, Xu J, Zhang H. et al. *Brucella* BioR regulator defines a complex regulatory mechanism for bacterial biotin metabolism. *J Bacteriol* 2013;**195**:3451–67. <https://doi.org/10.1128/JB.00378-13>
101. Cronan JE. Expression of the biotin biosynthetic operon of *Escherichia coli* is regulated by the rate of protein biotination. *J Biol Chem* 1988;**263**:10332–6.
102. Perkins JB, Bower S, Howitt CL. et al. Identification and characterization of transcripts from the biotin biosynthetic operon of *Bacillus subtilis*. *J Bacteriol* 1996;**178**:6361–5. <https://doi.org/10.1128/jb.178.21.6361-6365.1996>
103. Lazar N, Fay A, Nandakumar M. et al. Control of biotin biosynthesis in mycobacteria by a pyruvate carboxylase dependent metabolic signal. *Mol Microbiol* 2017;**106**:1018–31. <https://doi.org/10.1111/mmi.13865>
104. Schneider J, Peters-Wendisch P, Stansen KC. et al. Characterization of the biotin uptake system encoded by the biotin-inducible bioYMN operon of *Corynebacterium glutamicum*. *BMC Microbiol* 2012;**12**:6. <https://doi.org/10.1186/1471-2180-12-6>
105. Rodionov DA, Mironov AA, Gelfand MS. Conservation of the biotin regulon and the BirA regulatory signal in eubacteria and archaea. *Genome Res* 2002;**12**:1507–16. <https://doi.org/10.1101/gr.314502>
106. Vitko NP, Grosser MR, Khatri D. et al. Expanded glucose import capability affords *Staphylococcus aureus* optimized glycolytic flux during infection. *MBio* 2016;**7**:e00296–16. <https://doi.org/10.1128/mBio.00296-16>